Previous findings of the impact of miR-142-3p on tumour progression along with the data presented in this study, linking mutant p53R172H and DNMT1 expression, suggest that DNMT1 may be a potential therapeutic target in PDAC. Here, DNMT1 is linked to neoplasm.